[SMLE] Lambert-Eaton myasthenic syndrome with primary thymic marginal zone B-cell lymphoma: A case report

Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6501
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Mac OS X iPhone

[SMLE] Lambert-Eaton myasthenic syndrome with primary thymic marginal zone B-cell lymphoma: A case report

Message par RSS-Bot »


Respirol Case Rep. 2023 Apr 18;11(5):e01149. doi: 10.1002/rcr2.1149. eCollection 2023 May.

ABSTRACT

Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune paraneoplastic syndrome with proximal muscle weakness, that often complicates small cell lung cancer. It is known that neurological symptoms do not improve with malignancy treatment alone in many LEMS patients, therefore treatment is often difficult. Since Lambert-Eaton myasthenic syndrome is a rare disease with a frequency of about 1/100 that of myasthenia gravis, there are only a few case reports on malignancy complications other than small cell lung cancer. We report a LEMS patient in his 40s who was found to have an anterior mediastinal mass. We performed surgical resection and confirmed the diagnosis of primary thymic marginal zone B-cell lymphoma by pathological diagnosis using immunostaining. Thymectomy and malignant lymphoma treatment with rituximab had no effect on neurological symptoms. The neurological symptoms improved only after we provided comprehensive care with the haematology, neurology, and rehabilitation department.

PMID:37082169 | PMC:PMC10111402 | DOI:10.1002/rcr2.1149


Source: https://pubmed.ncbi.nlm.nih.gov/3708216 ... t6+86293ac
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Syndrome Myasthénique de Lambert-Eaton - SMLE »